Although the detection rate of NTRK fusions in GBM is relatively low, TRK inhibitors, which target NTRK fusions, have shown potential efficacy in CNS tumors and adult GBM in preclinical studies and clinical trials. The gene discussed is TPM3; the disease is glioblastoma.